These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of arginine vasopressin (AVP) on the pituitary-thyroid axis in the rat: Evidence that endogenous AVP, acting via V1 receptors, lowers TSH blood concentration.
    Author: Malendowicz LK, Spinazzi R, Nowak KW, Nussdorfer GG, Majchrzak M.
    Journal: Int J Mol Med; 2004 Jun; 13(6):869-72. PubMed ID: 15138627.
    Abstract:
    We have investigated the effects of the prolonged administration (2 or 8 days) of arginine-vasopressin (AVP), alone or with antagonists of its V1 and V2 receptors (V1-Ra and V2-Ra), on the rat pituitary-thyroid axis. In the 8-day, but not 2-day experiments, AVP raised thyroid weight, and the effect was prevented by V1-Ra. Morphometry showed that the AVP-induced increase in thyroid weight was mainly due to a rise in the stroma volume. In the 2-day, but not 8-day experiments, AVP lowered TSH plasma concentration, and the effect was annulled by V1-Ra. V1-Ra was ineffective per se, while V2-Ra lowered TSH blood level. AVP administration increased the level of circulating thyroid hormones, especially thyroxine (free and total T4). In the 2-day, but not 8-day experiments, this effect of AVP was blocked by both V1-Ra and V2-Ra. When administered alone V1-Ra and V2-Ra induced a small, but significant rise in T4 plasma concentration in both the 2-day and 8-day experiments. Collectively, these findings indicate that: i) AVP administration exerts a transient inhibitory effect on TSH secretion, and a more prolonged stimulatory action on thyroid secretion and growth, both of which are mainly mediated by the V1-R subtype; and ii) endogenous AVP exerts a clearcut tonic inhibitory effect on pituitary TSH release and doubtful regulatory actions on the thyroid gland.
    [Abstract] [Full Text] [Related] [New Search]